Advertisement

Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients

Published:August 15, 2017DOI:https://doi.org/10.1016/j.ejim.2017.08.016

      Highlights

      • Ischemic heart disease and COPD frequently coexist in the same patient.
      • The effects of COPD treatments on myocardial infarction presentation are evaluated.
      • Data from a large Italian multicentre registry are presented.
      • ICS/LABD treatment showed a protective effect on myocardial infarction presentation.

      Abstract

      Background

      Patients with myocardial infarction and concomitant COPD are at increased risk of poor clinical outcomes, including death, as compared to patients without COPD.

      Aim

      To investigate and compare the severity of the clinical presentation of ST-segment elevation myocardial infarction (STEMI) and of the short-(7 days) and long-term-(end of follow up) mortality in COPD patients treated with inhaled corticosteroids (ICS)/long-acting bronchodilator (LABD) - either long-acting beta2 agonist (LABA) or long-acting muscarinic antagonist (LAMA) - vs. any other inhaled treatments.

      Methods

      Data from the REAL (Registro Angioplastiche dell'Emilia-Romagna) Registry were obtained from a large prospective study population of 11,118 patients admitted to hospital for STEMI.

      Results

      From January 2003 to June 2009 we identified 2032 COPD patients admitted to hospital for STEMI. Eight hundred and twenty (40%) COPD patients were on ICS/LABD treatment (of which 55% on ICS/LABA) prior to admission. After adjustment for potential confounding factors, ICS/LABD treatment before STEMI was an independent predictor of reduced risk of pulmonary oedema and cardiogenic shock (OR 0.5, 95%CI 0.3–0.72, p < 0.01; OR 0.7, 95%CI 0.4–0.9, p = 0.03, respectively). ICS/LABD treatment was associated to reduced 7-days mortality (OR 0.54, 95%CI 0.29–0.98, p = 0.045) compared to other inhaled regimens. ICS/LABD-treated did not affect long-term (median 4 years) mortality. After hospital discharge, the proportion of ICS/LABD treated patients decreased significantly at 6 months and afterwards after the STEMI episode.

      Conclusion

      Our data provide preliminary evidence that in COPD patients ICS/LABD treatment reduces the severity of STEMI acute-phase clinical manifestations compared to other inhaled treatments.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. 2014 ESC/EACTS guidelines on myocardial revascularization.
        Eur Heart J. 2014; 35: 2541-2619https://doi.org/10.1093/eurheartj/ehu278
        • Global Initiative for Chronic Obstructive Lung Disease (GOLD)
        Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (UPDATED 2017).
        (Available from:) ([n.d.])
        • Chen W.
        • Thomas J.
        • Sadatsafavi M.
        • Fitzgerald J.M.
        Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
        Lancet Respir Med. 2015; 3: 631-639https://doi.org/10.1016/S2213-2600(15)00241-6
        • Campo G.
        • Pavasini R.
        • Barbetta C.
        • MSc E.M.
        • Mascetti S.
        • Biscaglia S.
        • et al.
        Int J Cardiol. 2016; 222: 806-812https://doi.org/10.1016/j.ijcard.2016.08.030
        • Almagro P.
        • Lapuente A.
        • Pareja J.
        • Yun S.
        • Garcia M.E.
        • Padilla F.
        • et al.
        Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study.
        Int J Chron Obstruct Pulmon Dis. 2015; 10: 1353-1361https://doi.org/10.2147/COPD.S84482
        • Campo G.
        • Guastaroba P.
        • Marzocchi A.
        • Santarelli A.
        • Varani E.
        • Vignali L.
        • et al.
        Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention.
        Chest. 2013; 144: 750https://doi.org/10.1378/chest.12-2313
        • Wakabayashi K.
        • Gonzalez M.A.
        • Delhaye C.
        • Ben-Dor I.
        • Maluenda G.
        • Collins S.D.
        • et al.
        Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction.
        Am J Cardiol. 2010; 106: 305-309https://doi.org/10.1016/j.amjcard.2010.03.026
        • Seemungal T.A.
        • Donaldson G.C.
        • Paul E.A.
        • Bestall J.C.
        • Jeffries D.J.
        • Wedzicha J.A.
        Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 1998; 157: 1418-1422
        • Donaldson G.C.
        • Seemungal T.A.R.
        • Bhowmik A.
        • Wedzicha J.A.
        Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.
        Thorax. 2002; 57: 847-852
        • Contoli M.
        • Baraldo S.
        • Marku B.
        • Casolari P.
        • Marwick J.A.
        • Turato G.
        • et al.
        Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up.
        J Allergy Clin Immunol. 2010; 125: 830-837https://doi.org/10.1016/j.jaci.2010.01.003
        • Soler-Catalun J.
        • Martınez-Garcia M.
        • Sanchez R.
        • Salcedo E.
        • Navarro M.
        • Ochando R.
        Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.
        Thorax. 2005; 60: 925-931https://doi.org/10.1136/thx.2005.040527
        • Mallia P.
        • Contoli M.
        • Caramori G.
        • Pandit A.
        • Johnston S.L.
        • Papi A.
        Exacerbations of asthma and chronic obstructive pulmonary disease (COPD): focus on virus induced exacerbations.
        Curr Pharm Des. 2007; 13: 73-97
        • Wedzicha J.A.
        • Seemungal T.A.R.
        COPD exacerbations: defining their cause and prevention.
        Lancet. 2007; 370: 786-796https://doi.org/10.1016/S0140-6736(07)61382-8
        • Beghe B.
        • Verduri A.
        • Roca M.
        • Fabbri L.M.
        Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD.
        Eur Respir J. 2013; 41: 993-995https://doi.org/10.1183/09031936.00180812
        • Campo G.
        • Pavasini R.
        • Malagù M.
        • Punzetti S.
        • Napoli N.
        • Guerzoni F.
        • et al.
        Relationship between troponin elevation, cardiovascular history and adverse events in patients with acute exacerbation of COPD.
        COPD. 2015; ([150316065057007])https://doi.org/10.3109/15412555.2014.995293
        • Patel A.R.
        • Kowlessar B.S.
        • Donaldson G.C.
        • Mackay A.J.
        • Singh R.
        • George S.N.
        • et al.
        Cardiovascular risk, myocardial injury and exacerbations of chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2013; https://doi.org/10.1164/rccm.201306-1170OC
        • Donaldson G.C.
        • Hurst J.R.
        • Smith C.J.
        • Hubbard R.B.
        • Wedzicha J.A.
        Increased risk of myocardial infarction and stroke following exacerbation of COPD.
        Chest. 2010; 137: 1091-1097https://doi.org/10.1378/chest.09-2029
        • Campo G.
        • Saia F.
        • Guastaroba P.
        • Marchesini J.
        • Varani E.
        • Manari A.
        • et al.
        Prognostic impact of hospital readmissions after primary percutaneous coronary intervention.
        Arch Intern Med. 2011; 171: 1948-1949https://doi.org/10.1001/archinternmed.2011.536
        • Marzocchi A.
        • Piovaccari G.
        • Manari A.
        • Aurier E.
        • Benassi A.
        • Saia F.
        • et al.
        Comparison of effectiveness of sirolimus-eluting stents versus bare metal stents for percutaneous coronary intervention in patients at high risk for coronary restenosis or clinical adverse events.
        Am J Cardiol. 2005; 95: 1409-1414https://doi.org/10.1016/j.amjcard.2005.01.096
        • Salisbury A.C.
        • Reid K.J.
        • Spertus J.A.
        Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes.
        Am J Cardiol. 2007; 99: 636-641https://doi.org/10.1016/j.amjcard.2006.09.112
        • Jones R.C.M.
        • Price D.
        • Ryan D.
        • Sims E.J.
        • Ziegenweidt von J.
        • Mascarenhas L.
        • et al.
        Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort.
        Lancet Respir Med. 2014; 2: 267-276https://doi.org/10.1016/S2213-2600(14)70008-6
        • Fabbri L.M.
        • Rabe K.F.
        From COPD to chronic systemic inflammatory syndrome?.
        Lancet. 2007; 370: 797-799https://doi.org/10.1016/S0140-6736(07)61383-X
        • Scichilone N.
        • Tuttolomondo A.
        • Maida C.
        • Benfante A.
        • Peluso J.
        • Cirrincione A.
        • et al.
        Arterial stiffness in symptomatic smokers with normal lung function.
        ERJ Open Res. 2017; 3: 00037-02017https://doi.org/10.1183/23120541.00037-2017
        • Campo G.
        • Pavasini R.
        • Malagù M.
        • Mascetti S.
        • Biscaglia S.
        • Ceconi C.
        • et al.
        Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management.
        Cardiovasc Drugs Ther. 2015; https://doi.org/10.1007/s10557-014-6569-y
        • Campo G.
        • Vieceli Dalla Sega F.
        • Pavasini R.
        • Aquila G.
        • Gallo F.
        • Fortini F.
        • et al.
        Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease.
        Thromb Haemost. 2017; 117: 1208-1216https://doi.org/10.1160/TH16-12-0973
        • Gurbel P.A.
        • Bliden K.P.
        • Butler K.
        • Tantry U.S.
        • Gesheff T.
        • Wei C.
        • et al.
        Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
        Circulation. 2009; 120: 2577-2585https://doi.org/10.1161/CIRCULATIONAHA.109.912550
        • Brook R.D.
        • Anderson J.A.
        • Calverley P.M.
        • Celli B.R.
        • Crim C.
        • Denvir M.A.
        • et al.
        Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.
        Heart. 2017; ([heartjnl–2016–310897])https://doi.org/10.1136/heartjnl-2016-310897
        • Vestbo J.
        • Anderson J.A.
        • Brook R.D.
        • Calverley P.M.A.
        • Celli B.R.
        • Crim C.
        • et al.
        Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
        Lancet. 2016; 387: 1817-1826https://doi.org/10.1016/S0140-6736(16)30069-1
        • Hunter R.W.
        • Bailey M.A.
        Glucocorticoids and 11β-hydroxysteroid dehydrogenases: mechanisms for hypertension.
        Curr Opin Pharmacol. 2015; 21: 105-114https://doi.org/10.1016/j.coph.2015.01.005
        • Cruz-Topete D.
        • Myers P.H.
        • Foley J.F.
        • Willis M.S.
        • Cidlowski J.A.
        Corticosteroids are essential for maintaining cardiovascular function in male mice.
        Endocrinology. 2016; 157: 2759-2771https://doi.org/10.1210/en.2015-1604
        • Nebelsiek T.
        • Beiras-Fernandez A.
        • Kilger E.
        • Möhnle P.
        • Weis F.
        Routine use of corticosteroids to prevent inflammation response in cardiac surgery.
        Recent Pat Cardiovasc Drug Discov. 2012; 7: 170-174
        • Kohsaka S.
        • Menon V.
        • Lowe A.M.
        • Lange M.
        • Dzavik V.
        • Sleeper L.A.
        • et al.
        Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock.
        Arch Intern Med. 2005; 165: 1643-1650https://doi.org/10.1001/archinte.165.14.1643
        • Keatings V.M.
        • Jatakanon A.
        • Worsdell Y.M.
        • Barnes P.J.
        Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD.
        Am J Respir Crit Care Med. 1997; 155: 542-548https://doi.org/10.1164/ajrccm.155.2.9032192
        • Culpitt S.V.
        • Maziak W.
        • Loukidis S.
        • Nightingale J.A.
        • Matthews J.L.
        • Barnes P.J.
        Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 1999; 160: 1635-1639https://doi.org/10.1164/ajrccm.160.5.9811058
        • Lagrand W.K.
        • Visser C.A.
        • Hermens W.T.
        • Niessen H.W.
        • Verheugt F.W.
        • Wolbink G.J.
        • et al.
        C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?.
        Circulation. 1999; 100: 96-102
        • Man S.F.P.
        • Sin D.D.
        Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease.
        Proc Am Thorac Soc. 2005; 2: 78-82https://doi.org/10.1513/pats.200406-034MS
        • Santus P.
        • Radovanovic D.
        • Di Marco S.
        • Valenti V.
        • Raccanelli R.
        • Blasi F.
        • et al.
        Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial.
        Int J Chron Obstruct Pulmon Dis. 2015; 10: 1917-1923https://doi.org/10.2147/COPD.S91684
        • Stone I.S.
        • Barnes N.C.
        • James W.-Y.
        • Midwinter D.
        • Boubertakh R.
        • Follows R.
        • et al.
        Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease. A randomized controlled trial.
        Am J Respir Crit Care Med. 2016; 193: 717-726https://doi.org/10.1164/rccm.201508-1647OC
        • Calverley P.M.A.
        • Anderson J.A.
        • Brook R.D.
        • Crim C.
        • Gallot N.
        • Kilbride S.
        • et al.
        Fluticasone furoate, vilanterol and lung function decline in patients with moderate COPD and heightened cardiovascular risk.
        Am J Respir Crit Care Med. 2017; ([rccm.201610–2086OC])https://doi.org/10.1164/rccm.201610-2086OC
        • Silverman H.S.
        • Pfeifer M.P.
        Relation between use of anti-inflammatory agents and left ventricular free wall rupture during acute myocardial infarction.
        Am J Cardiol. 1987; 59: 363-364
        • Campo G.
        • Saia F.
        • Percoco G.
        • Manari A.
        • Santarelli A.
        • Vignali L.
        • et al.
        Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry.
        Int J Cardiol. 2010; 140: 154-160https://doi.org/10.1016/j.ijcard.2008.11.021
        • Woodruff P.G.
        • Barr R.G.
        • Bleecker E.
        • Christenson S.A.
        • Couper D.
        • Curtis J.L.
        • et al.
        Clinical significance of symptoms in smokers with preserved pulmonary function ONLINE.
        N Engl J Med. 2016; 374: 1811-1821https://doi.org/10.1056/NEJMoa1505971